In preclinical stroke models it has been shown that pharmacological blockade of Nogo, Nogo receptor antagonism, or digestion of chondroitin sulfate proteoglycans by chondroitinase induce axonal sprouting and promote functional recovery [7–9]. The gene discussed is RTN4; the disease is stroke disorder.